Business (Health)
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Deals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Deals
OTC Naloxone NDA In US Gets Fast Track Status
Nonprofit HRT reached a commercial supply agreement for a firm to produce its RiVive naloxone nasal spray still in development after FDA granted fast frack designation for its OTC switch NDA.
Dermapharm Expands Natural Offering With France's Arkopharma
Germany's Dermapharm will pay €450m to acquire herbal specialist Arkopharma to expand its footprint in Europe's consumer health market in countries such as France, Spain and Italy.
GSK Exits Consumer Health With Haleon Launch
The global market leader in consumer health is now Haleon following its separation from GSK after more than two years of planning.
Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Business Strategies
Dutch Firm TheOTCLab Gets EU MDR Approval For Dr. Yglo OTC Wart Device
Amsterdam-based TheOTCLab has received an EU CE mark for its new wart and verruca OTC freezing device Dr. Yglo. The firm plans to launch the product in Europe in Italy, Portugal, Estonia, Latvia, and Lithuania, and will separately look to take it further afield to the US and South Africa.
UK Product Approvals: J&J Expands Sudafed And Nicorette Offerings
The UK's MHRA has approved the Rx-to-OTC switch of J&J's Sudafed Plus nasal spray (xylometazoline hydrochloride/dexpanthenol) and given the green light for the company to add new pack sizes to its Nicorette QuickMist and QuickMist Smart Track products.
Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.
Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Sales & Earnings
Inflation, Supply Chain And Private Label Pressures: Consumer Health Leaders Talk ‘Big Picture’ Challenges
OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we’ve culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.
Beiersdorf Is Having Record Year For Sun Care, Seeing China Recovery, But Full-Year Outlook Is Guarded
The Hamburg, Germany-based firm defied economic and political headwinds and China troubles in the fiscal 2022 first half to book organic net sales growth of 10.5% to €4.5bn worldwide. Despite optimism about China recovery, sun care, and its recent Chantecaille acquisition, Beiersdorf is projecting a slowdown in the second half in what remains a volatile operating environment.
Perrigo Starts Supply Chain Overhaul After Filing OTC Birth Control NDA, Launching Nasonex Switch
Along with Q2 results including reported net sales up 14.3% to $1.12bn, Perrigo announces overhaul of its supply chain expected to generate $100m to $300m in net cost savings and creation of women's health, skin care business units.
Litigation
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Health & Legal Issues
First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride
Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.
J&J Pulls Plug On Talc Across Its Baby Powder Portfolio, Shifts To Cornstarch-Based Products
As it did when it halted sales in US and Canada in 2020, J&J’s latest announcement attributes its decision as coming from a “portfolio assessment” and stated it remains confident in using talc in baby powder and cosmetics.
Benzene Suits Against US Personal-Care Firms Appear Headed In One Direction: Settlement
The latest in litigation against Unilever, P&G, Beiersdorf and J&J alleging violations for selling personal-care products contaminated with benzene.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.